ArticleBMC clinical pharmacology2005

Pharmacovigilance program to monitor adverse reactions of recombinant streptokinase in acute myocardial infarction.

Blas Y Betancourt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.